Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.

Foundation Medicine and Memorial Sloan-Kettering Cancer Center have announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer.

Leaders in hematology from Memorial Sloan-Kettering will help accelerate product development by providing clinical and genomic expertise.

This product complements FoundationOne™, Foundation Medicine’s first product, which offers a similar fully informative genomic profile for solid tumors and likewise provides a concise report to assist physicians in matching patients with the targeted drugs or clinical trials best suited for their unique cancer. FoundationOne was launched in 2012.

“The development of clinical grade sequencing is rapidly changing the practice of oncology, enabling us to more precisely understand and target the genomic alterations that drive a patient’s individual cancer,” said Craig B. Thompson, M.D., president and chief executive officer of Memorial Sloan-Kettering Cancer Center.

Thompson continued, “We are partnering with Foundation Medicine to develop a best-in-class assay for hematologic cancers because we view achieving this goal as an extension of our mission as a comprehensive cancer center: making it possible for all patients to be treated with the therapy that is matched with their individual cancer.”

“Memorial Sloan-Kettering is one of the world’s premier cancer centers with deep scientific and clinical understanding of hematologic cancers and a commitment to driving a new genomic paradigm of individualized cancer care,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine.

Pellini continued, “Our approach is to collaborate with leaders like Memorial Sloan-Kettering across all areas of clinical oncology and cancer genomics and seek partners who are equally committed to the changing paradigm of cancer care. This is the ideal partnership to support the development of our new product for patients with hematologic malignancies.”

This new test is being developed using RNA sequencing in addition to DNA sequencing to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies.

Similar to FoundationOne, the new hematologic malignancy test will assist physicians by matching these alterations with targeted treatment options that may be relevant to the patient’s genomic profile based on a comprehensive review of published literature.

The test will be based on technology, methods and computational algorithms developed by Foundation Medicine, and Foundation Medicine will commercialize the test both in the United States and internationally.

Memorial Sloan-Kettering will help accelerate the development and optimization of the product by contributing their clinical and genomic expertise in hematologic malignancies.

Foundation Medicine operates a CLIA-certified lab in Cambridge, Mass. and receives clinical patient samples from academic medical centers and community hospitals all over the world. The new test is expected to be commercially available by year-end 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine Announces $42.5 Million Series B Financing
Syndicate includes leading public and strategic investors; proceeds will expand commercial operations and accelerate adoption of FoundationOne™.
Monday, October 01, 2012
Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine Announces Collaboration with Sanofi
Fifth partnership will help translate cancer genomic science to clinical results. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.
Friday, January 13, 2012
Foundation Medicine Appoints Molecular Diagnostics Industry Leader Maureen T. Cronin, Ph.D., as Senior Vice President of Research and Product Development
Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, have announced the appointment of Maureen T. Cronin, Ph.D., to the newly created position of senior vice president, research and product development.
Tuesday, November 16, 2010
Scientific News
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!